Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
Completed
- Conditions
- Central Nervous System Lymphoma
- Registration Number
- NCT03342586
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Brief Summary
The purpose of this study is to test resting state functional Magnetic Resonance Imaging (rsfMRI) scans to see if rsfMRI scans are better than the standard task based fMRI scans at diagnosing or monitoring central nervous system lymphoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
- Immunocompetent patients with newly diagnosed or recurrent non-Hodgkins lymphoma involving the brain (primary or secondary), as demonstrated by MRI and histologic confirmation either by positive CSF cytology for lymphoma or a monoclonal lymphocyte population defined by cell surface markers, vitreous or uvea biopsy or brain biopsy
- Age 18-80 years
- Treatment plan for HDC-ASCT
- Fluent in English
- Patients who in the judgment of the investigators and/or consenting professional, are able to understand the purpose of the study and provide informed consent will be included.
Exclusion Criteria
- Claustrophobia
- Any contraindication to the use of contrast and/or general guidelines for MR imaging as per standard Department of Radiology imaging guidelines
- Unable to cooperate for MRI
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in resting state brain networks over time in participants with central nervous system lymphoma before and after treatment with high-dose chemotherapy with autologous stem cell transplantation through resting state fMRI results 6 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie rsfMRI's potential to detect neurotoxicity in CNS lymphoma patients post-HDCT and ASCT?
How does resting state functional connectivity compare to task-based fMRI in monitoring CNS lymphoma treatment response after high dose chemotherapy?
Which biomarkers correlate with neurotoxicity outcomes in NCT03342586 CNS lymphoma functional MRI study?
What adverse events are associated with high dose chemotherapy and autologous stem cell transplant in primary CNS lymphoma patients?
Are there combination approaches involving rsfMRI and other diagnostic tests for improved CNS lymphoma neurotoxicity assessment?
Trial Locations
- Locations (1)
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center🇺🇸New York, New York, United States